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ABSTRACT Bacterial infections of the genital tract (gon-
orrhea, chlamydia, chancrold, syphilis) are common and cause
sArm nt morbidity. Theirimp is heightened by recent
appreciation of their roles In filtion transmission of the
human sImmunodecency (HV). Each is capable of
causing repeated infections, sueslg lack of permanent
broadly effective inuunity. An effective vaccine has yet to be
developed for any of these dises. Rapid progres in under-
standing the molecular basis for pathogenesis of infection,
including mechansms for escape from otherwise effective
immune surveillance andm sms for causing injury to host
cells, has simiated renewed efforts to make vaccines for some
of these infections. Progress has been greatest for Neisseria
gonorvhoeae and Chamydia tmchomais. Present empais is
on the major or pripl outer membrane proteins of N.
gonorrhoeae and C. trachomats, based on evidence for neu-
traliing antibodies directed against surface-exposed variable
domains of each of these proteins. Other surface-exposed
proteins, iluding the iron-repressible transferrin receptor in
gonococci and certain heat-shock proteins in chuamydia, also
may be targets for vaccines. Although much rem to be
learned, cautio mism is warranted.
The majority of the world research effort on sexually trans-
mitted infections is now focused on human immunodefi-
ciency virus (HIV) infection, for the understandable reasons
that HIV infections are spreading dramatically around the
globe, are increasingly spread by heterosexual behaviors,
and are ultimately lethal. Current treatment for HIV is only
of modest benefit, and intense efforts to create an HIV
vaccine have been thwarted to date by the antigenic vari-
ability of the virus.
The curable sexually transmitted diseases (STDs) caused
by bacterial pathogens (Neisseria gonorrhoeae, Treponema
pallidum, Haemophilus ducreyi, and Chlamydia trachoma-
tis) have received relatively less research and clinical atten-
tion compared with HIV. Use of a combination of ap-
proaches, including public education and accessible treat-
ment clinics, in many nations in the industrialized West has
resulted in dramatic declines in incidence of most bacterial
STDs in the last 10-14 years, particularly gonorrhea (1, 2).
The situation in the United States is less optimistic. Whereas
gonorrhea has declined by 40%, heterosexually transmitted
syphilis, congenital syphilis, chancroid, and chlamydia have
increased (3). Problems with these infections are even worse
in many developing and underdeveloped nations in Africa,
Asia, and elsewhere. Increasing antibiotic resistance in gono-
cocci (3) and H. ducreyi (4) has necessitated use of newer,
more expensive, antimicrobials, a circumstance that can
prohibit effective therapy in developing nations.
The importance of the bacterial STDs rests in part on their
adverse effects on reproductive health. Both gonorrhea and
genital chlamydia are major causes of salpingitis, ectopic
pregnancy, and infertility. A sense of urgency for the control
of these diseases has emerged recently because of evidence
that they significantly increase the rate of HIV transmission
between sexual partners (5-9). Genital ulcer disease is rec-
ognized as an important cofactor for HIV transmission (7-9)
and H. ducreyi and T. pallidum are prominent causes of the
genital ulcer syndrome. The effects of gonorrhea and genital
chlamydia on HIV transmission (5, 6) may be due to microul-
ceration (10) and increased local accumulation of activated
lymphocytes and macrophages, with a corresponding in-
crease in release of HIV into genital secretions (11).
Because of the apparent roles of bacterial STDs in HIV
transmission, the World Health Organization has concluded
that strategies to control HIV should include development of
effective programs for control of bacterial STI)s (12). Al-
though experience in several nations shows this can be
accomplished (at least temporarily) without vaccines (1, 2),
experience in other nations, including the United States,
suggests that this is a difficult task. Vaccines against bacterial
STDs would improve the public health and would offer
long-lasting and cost-effective solutions to common and
expensive problems. The question is, can such vaccines be
developed? This paper briefly reviews relevant progress in
research towards this goal.
CHANCROID
Chancroid is an ulcerating cutaneous infection caused by H.
ducreyi. Infection may persist for months without effective
antibiotic therapy. In earlier times, clinicians inoculated
normal skin with pus taken from genital ulcers ofthe patient,
and development of typical ulcerating lesions after such
inoculation was used to confirm the diagnosis of chancroid
(13). Indeed, Ducrey (13) was able to serially propagate the
infectious agent at least 15 times in the same individual,
indicating that little or no immunity occurs in naturally
acquired infection. Today, diagnosis is made by in vitro
culture. A renewed surge of research interest occurred after
recognition that H. ducreyi is a cofactor for HIV transmission
Abbreviations: HIV, human immunodeficiency virus; STDs, sexu-
ally transmitted diseases; mAb, monoclonal antibody; LOS, lipo-
oligosaccharide; MOMP, major outer membrane protein; TH, T-help.
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(7-9), and factors involved in pathogenesis are beginning to
be delineated (14).
The cardinal feature of chancroid is the development of
ulcers on stratified squamous epithelium, which suggests that
H. ducreyi might produce cytotoxins or other tissue-
destructive extracellular products. Recent evidence shows
that many H. ducreyi isolates apparently do produce cyto-
toxins (15). Lagergard and Purven (16) found that injection of
live H. ducreyi into rabbits resulted in low-titer anti-cytotoxin
antibodies; a subsequent injection of live organisms resulted
in neutralizing antibodies. Immunization of rabbits with
crude preparations of cytotoxin (cell sonicates) resulted in
neutralizing anti-cytotoxin antibodies that cross-reacted in
similar titers with each of 12 heterologous cytotoxin-
producing strains (16). Immunization with non-cytotoxin-
producing H. ducreyi or other Gram-negative bacteria failed
to produce cytotoxin-neutralizing antibodies (16). However,
natural infection of humans apparently results in anti-
cytotoxin antibodies, without evident protection from dis-
ease (16). The role of cytotoxin in the pathogenesis ofhuman
chancroid is unclear at present, and much remains to be
learned about the genetics, biochemistry, and immunobiol-
ogy of the putative cytotoxins. Interest in the cytotoxins is
prompted, of course, by evidence that many other cytotoxins
can be used to create effective vaccines, including diphtheria
toxin.
A variety of other H. ducreyi proteins also have been
identified, including outer membrane proteins and pili (14).
Some of these proteins appear to be antigenically variable
during infection of a subcutaneous chamber, a property that
could explain the ability of H. ducreyi to persist in vivo (17).
Little is known about the nature of the immune response in
human chancroid, although there is evidence for both a T-cell
(18) and a B-cell response.
SYPHILIS
The question of immunity in syphilis has long been the
subject of investigation. Some level of protective immunity
was suggested by early observations that only one-third of
untreated cases of human syphilis developed late complica-
tions of disease (19). During early stages of active untreated
infection, immunity to reinfection seemed to be present, the
so-called "chancre immunity"; studies ofexperimental syph-
ilis in rabbits confirmed this phenomenon (20). Development
of chancre immunity is correlated with a vigorous humoral
and cellular immune response to multiple antigens (21). After
several weeks of untreated early syphilis, treponemes are
cleared from the primary and secondary lesions. However,
viable treponemes persist in untreated experimental animals
for years in sites such as lymph nodes (22), suggesting that T.
pallidum is capable of evading the immune response. Con-
sistent with this is the protracted course of untreated disease
in humans, with its characteristic waxing and waning in the
first 1-2 years, followed by long intervals that ultimately (in
one-third of cases) lead to late destructive lesions of the
heart, central nervous system, or other organs.
Support for the possibility that an effective syphilis vaccine
can be developed rests in large part on studies of experimen-
tal syphilis in human prison volunteers, conducted nearly 40
years ago at Sing Sing Prison in New York State by Magnu-
son et al. (23). They injected 105 (>100 times the ID50) live T.
pallidum harvested from rabbits into the skin of 62 adult
males, 60 ofwhom were followed either until they developed
lesions or until 4 months had elapsed. All were treated with
penicillin at the end of the study. Each of 8 controls (no prior
syphilis) developed dark-field-positive (spirochetes visible in
dark-field microscopy) papules or ulcers at the inoculation
site, whereas no lesions developed in each of 5 men with
previously untreated latent syphilis. Among 11 men previ-
ously treated for early syphilis, 9 developed dark-field-
positive lesions, and the other 2 developed dark-field-
negative lesions. Among 31 men previously treated for late or
congenital syphilis, only 2 developed dark-field-positive le-
sions, 15 developed dark-field-negative lesions (limited im-
munity?), and 14 appeared to be totally immune. Thus,
durable immunity developed in many, but not all, men treated
previously for natural infection, although at least several
years of untreated infection were required to provide immu-
nity.
Studies of immunity to T. pallidum in rabbits or hamsters
confirmed the existence of slowly developed immunity. Both
humoral and cellular arms of the immune system are impor-
tant to immunity in animals (24-28). Antibodies with both
neutralizing (27) and opsonic (28) activities, either of which
could contribute to immunity, develop during infection.
Mechanisms by which treponemes persist in the presence
of vigorous IgG, IgM, and cellular immune responses to
multiple antigens (reviewed in ref. 29) are unknown. Studies
of the physiology, biochemistry, and genetics of T. pallidum
have been limited because the organisms still cannot be
grown outside of animals, and because of lack of a genetic
system for constructing mutants of T. pallidum. Antigenic
structures seem stable during animal passage, and there is no
evidence of the type of phase and antigenic variation or
blocking antibodies that have confounded the search for a
vaccine against gonorrhea. Persistence in the face of a
vigorous antibody response could be due to intracellular
localization, although the pathogenesis of T. pallidum infec-
tions seems to involve penetration between cells (30) rather
than survival within epithelial cells or phagocytes.
One factor that may contribute to the persistence of T.
pallidum is the apparent paucity of proteins in the outer
membranes or envelope of the organism, which has been
demonstrated by freeze-fracture techniques by two groups
(31, 32). When compared with Escherichia coli, T. pallidum
has only about 1% the density of integral outer membrane
proteins. Proteins in the outer membrane of T. pallidum thus
are termed TROMPs-treponemal rare outer membrane pro-
teins. T. pallidum also lacks lipopolysaccharide in its outer
membrane. Identities ofTROMPs have been elusive to date,
although searching recombinant T. pallidum libraries for
phoA (alkaline phosphatase) fusions has identified T. palli-
dum genes that encode membrane-spanning proteins con-
taining N-terminal signal sequences (33). Progress in the
molecular characterization of T. pallidum genes and their
predicted proteins by use ofrecombinant DNA technology is
impressive (29).
Initial attempts to develop vaccines for syphilis employed
the Nichols strain of T. pallidum, which fully retained its
virulence for humans after decades of serial passage in rabbit
testicles (23). Vaccination of rabbits with T. pallidum killed
by either irradiation (34) or prolonged cold storage (35)
resulted in immunity, but multiple large doses were required
over considerable periods of time, limiting enthusiasm for
analogous approaches in humans. Subsequently, Fitzgerald
induced considerable immunity in rabbits with a single in-
jection of heat-killed T. pallidum, when the animals were
pretreated with cyclophosphamide and given various adju-
vants (36). Fitzgerald concluded that whole-cell vaccines
caused immunosuppression, which could be overcome by the
sequential use of cyclophosphamide and adjuvants. No con-
firmatory results have yet been reported.
Current efforts to develop a syphilis vaccine focus on
recombinant T. pallidum proteins. Three of these show
limited efficacy in animals. An antigen designated TpN19 (or
previously 4D) elicited partial protection in rabbits (37).
TpN19 is interesting because in its native form it assembles
into an oligomeric ringlike structure (38), although its func-
tion in pathogenesis or in the physiology of T. pallidum is
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unknown. Vaccination with recombinant endoflagellar pro-
tein (39) or another protein designated either TpN36 or TmpB
(40) also resulted in partial protection in animals.
These results do not permit conclusions about develop-
ment of vaccines for syphilis, other than that some progress
is being made. Difficulties in working with the organism are
considerable, but application of modem biotechnology can
be expected to hasten progress if funding for the few groups
working on syphilis is stable.
GONORRHEA
Gonorrhea is a common disease and was known to ancient
physicians. The quest for a vaccine is not new, and crude
whole-cell vaccines were actually used as immunotherapy in
the preantibiotic era (41). It is not possible to judge the
efficacy of the old gonococcal vaccines because of insuffi-
cient description of the experiments and lack of controls, yet
anecdotal experience suggested that modest doses of the
homologous strain were useful (41). In more recent times, a
variety of crude or partially purified antigens were used to
vaccinate experimental animals against gonorrhea, with mod-
estly encouraging results. For instance, immunization of
chimpanzees with a whole-cell killed vaccine made from a
chimpanzee virulent isolate conferred partial resistance to
urethral challenge (42). Most current studies, however, are
focused on purified and well-characterized antigens.
There are lessons to be derived from study of the course of
untreated natural gonococcal infection. Symptomatic uro-
genital gonorrhea eventually subsided into a nonsymptomatic
state in the preantibiotic era, and many patients became
culture-negative and noninfectious for their partners (41, 43).
By inference, the immune response was effective in control-
ling infection. However, immunity apparently was strain
specific, since patients commonly reacquired gonorrhea
many times. James Boswell's superb description of his 29
separate bouts of urogenital "gonorrhea" (some of which
undoubtedly were due to C. trachomatis) illustrates the point
(reviewed in ref. 44). Strain-specific immunity to genital
gonorrhea was claimed in a recent study of recurrent gonor-
rhea in female prostitutes in Nairobi, most of whom were
immunosuppressed because of infection by HIV. Reinfection
was common, but was less likely to be due to strains
exhibiting the same serovar of principal outer membrane
protein, porin (Por) than by other Por serovars, suggesting
partial immunity based on Por-specific epitopes (45). Subse-
quent work in the same population showed that presence of
serum antibodies to Por was not correlated with protection
(46). No attempt was made in the latter study to determine
whether serovar-specific serum or genital Por antibodies to
surface-exposed epitopes were correlated with protection
from reinfection, which are the type of data one would desire,
based on the earlier work.
for as a Vaccine Candidate. Por is one of the antigens
currently being studied as a possible vaccine. Por is the most
abundant membrane protein, is expressed constitutively, and
does not undergo high-frequency phase or antigenic variation
in vitro or in vivo. Clinical isolates, however, do exhibit
antigenic differences in some surface-exposed domains, pre-
sumably as a result of low-frequency -mutations of por that
allow escape from anti-Por antibodies (47). Some evidence
suggests that Por participates in pathogenesis by translocat-
ing into eukaryotic cells (48), which might promote invasion,
or in the case of neutrophils, apparently impairs neutrophil
function (49).
Prior to the epidemiological studies of Nairobi prostitutes
(45, 46), the possibility of a For vaccine was suggested by
Heckels and colleagues (50, 51), who showed that certain
monoclonal antibodies (mAbs) against Por were bactericidal,
stimulated chemiluminescence of neutrophils, and reduced
toxicity to cultured epithelial cells. Moreover, some of the
potentially protective mAbs reacted widely with either one or
the other of the two main Por-based serogroups of gono-
cocci-i.e., with strains of either the PorA or PorB sero-
groups (50, 51).
The por structural genes from several isolates have been
cloned and sequenced (52, 53), allowing comparisons of the
amino acid sequences of different Por molecules. PorA and
PorB are closely related to each other and are products of
variants of a single por gene (52, 53). There are multiple
predicted membrane-spanning domains and models predict
eight surface-exposed loops (54). By use of synthetic peptide
technology, the common PorB epitope that reacts with the
broadly protective PorB-specific mAb SM24 was defined as
YSIP (55). The common PorA epitope that reacts with the
broadly protective PorA-specific mAb SM101 (51) appears to
be conformation dependent and cannot be localized to a
single linear Por domain (53).
Elkins et al. (56) studied the immunobiology of polyclonal
rabbit antisera raised against six synthetic Por peptides, four
for PorA strain FA19 and two for PorB strain MS11. Results
were encouraging in that polyclonal IgG purified from serum
raised against the most N-terminal surface-exposed loop
(loop 1) were bactericidal not only for the homologous strain
but also for many other serological variants (serovars) of the
same serogroup and to a limited extent for serovars of the
other serogroup.
Purified Por also has been evaluated as a vaccine in
animals, using in vitro bactericidal and opsonic assays as
surrogates for possible protection of humans. Wetzler et al.
(57) purified Por from gonococci containing a mutation in
rmp, which encodes the reduction-modifiable protein (Rmp)
formerly designated PIll; the importance of using an rmp
mutant was in removal of the highly immunogenic Rmp
antigen, which stimulates production of complement-fixing,
but generally nonbactericidal, antibodies that block the bac-
tericidal effects of anti-lipooligosaccharide (LOS) or anti-Por
antibodies (58). Since mAbs against Rmp, Por, or LOS
immunoprecipitate all three molecules, they apparently are
tightly associated in clumps or patches in the outer mem-
brane, helping to explain why antibodies against Rmp block
bactericidal effects of anti-Por or anti-LOS. Using purified
Por free ofRmp contamination, Wetzler et al. (59, 60) showed
that Por liposomes were highly immunogenic and resulted in
bactericidal and opsonic antibodies that recognized surface-
exposed epitopes.
Elkins et al. (unpublished data) purified recombinant Por
(rPor) expressed from an inducible promoter in E. coli. This
approach has the potential advantages of permitting easy
growth ,of large batches of cells, allowing use of novel hybrid
PorA/PorB molecules (53), and also avoiding Rmp contam-
ination. E. coli and other Gram-negative bacteria contain an
outer membrane protein, OmpA, that exhibits significant
C-terminal homology with Rmp (61), but rPor can be purified
with <0.5% OmpA contamination, and anti-OmpA polyclo-
nal sera do not react with Rmp (unpublished data). Immuni-
zation of rabbits with liposomal rPor purified with decyl
(3-D-maltoside so as to retain some conformational epitopes
resulted in immune sera that bound well to Por on whole
gonococci and exhibited opsonic, but not bactericidal, activ-
ity (unpublished data). Lack of bactericidal activity was not
due to blocking antibodies, since gonococcal rmp mutants
also were resistant to killing by anti-rPor rabbit sera.
A problem for all Por vaccines concerns the effects of
sialylation of LOS. Sialylation ofLOS, which lies physically
proximate to Por in the outer membrane, abolished the
bactericidal effect of anti-loop 1 peptide antisera by partially
masking surface exposure of Por epitopes on whole bacteria
and also by inhibition of complement activation (56). Sialy-
lation of LOS also abrogated bactericidal and opsonophago-
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cytic effects of anti-Por sera (60). Since gonococcal LOS is
sialylated in vivo (62), vaccines based on these Por peptides
(and possibly any Por antigens) might be ineffective. Block-
ing of certain bactericidal anti-Por mAbs by sialylation was
incomplete, however, and could be overcome by use ofmore
mAb (C.E., unpublished data). This suggests that killing
might be possible with polyclonal anti-Por sera, if sufficiently
high titers or high-affinity antibodies could be raised.
Recently, it has been possible to construct recombinant
Salmonella typhimurium strains that express gonococcal Por
constitutively from thepor promoter without evident toxicity
to the host strain (63). This should allow studies of the
vaccine potential of Por delivered to the gut immune system
and of the ability of Por to protect against homologous and
heterologous infection in various (imperfect) mouse models
of gonococcal infection (64). The advantage of this approach
is that it should stimulate both humoral and mucosal immu-
nity, both of which presumably are required for an effective
gonococcal vaccine. It presumably will be possible to con-
struct analogous strains in attenuated hosts suitable for use in
humans, such as Salmonella typhi.
Ultimately, the utility ofPor vaccines will have to be tested
in humans. Recent studies of experimental urethral gonor-
rhea in male volunteers (65) show that such experiments can
be conducted ethically and safely. Sialylation of LOS in vivo
may effectively block any Por vaccine, but it should be
possible to test this hypothesis directly in humans soon. If
parenteral or oral vaccination with Por or peptides derived
from Por results in protection against an ID80 intraurethral
(male) challenge dose of the homologous strain, further
consideration of Por vaccines will be warranted.
Pili as a Vaccine Candidate. Pili (Pil) are filamentous
appendages composed of multiple pilin subunits, which func-
tion as adherence ligands. They appear to be necessary for
infection, since Pil- variants are essentially noninfectious in
experimental infection of male volunteers, whereas Pil+
gonococci are highly infectious under the same conditions
(66). It was soon recognized that PN undergo high-frequency
phase and antigenic variation (67-70) and that Pil antigenic
variants also exhibit different adherence properties (71, 72).
The mechanism of many Pil variations involves recombina-
tion (69) between the pilE (structural gene) and one of
multiple incomplete ("silent") variable copies of pil DNA
present in several chromosomal loci (67-70). The rapidity and
extent of Pil antigenic variation might help to explain how
gonococci escape a vigorous immune response, and/or how
gonococci rapidly adapt to adhere to quite different cells in
diverse ecological niches (cervix, urethra). Sequencing of
expressed pil genes from urethral isolates from previously
uninfected males with experimental gonorrhea shows exten-
sive variations, occurring so rapidly (first few days after
inoculation) that immune pressure is an unlikely explanation
(73) (H. S. Seifert, C. A. Wright, A. E. Jerse, M.S.C., and
J. G. Cannon, unpublished data). Extensive antigenic vari-
ation obviously might make it difficult to produce an effective
vaccine based on Pil, yet enthusiasm for a Pil-based vaccine
once was high because of evidence that anti-Pil antibodies
block adherence and are opsonic (72, 74, 75). Moreover,
certain regions of the pilin subunit are relatively conserved
(67, 75), and polyclonal rabbit sera against such partially
conserved pilin peptides reportedly blocked in vitro adher-
ence of heterologous gonococci (75). Enthusiasm lessened,
however, when subsequent studies failed to confirm surface
exposure of the conserved regions on intact pili expressed on
whole gonococci (76). Moreover, extensive work in Heckel's
laboratory showed that protective pilin mAbs all were di-
rected at highly variable pilin epitopes (72, 74).
While these elegant studies of Pil variations and immuno-
biology were being conducted, several laboratories worked in
a very directed fashion to implement a Pil vaccine for human
use. Intramuscular injection of purified Pil resulted in serum
(77) and genital IgG and IgA anti-Pil antibodies that blocked
adherence (78) and, in a historical study, partially protected
male volunteers from experimental urethral infection by the
homologous strain (79). There was some evidence of devel-
opment of cross-reactive anti-Pil antibodies (78, 79). A field
trial of a vaccine composed of a single antigenic type of
gonococcal Pil was conducted in Korea, and as might have
been anticipated because of extensive Pil antigenic variation,
there was no evidence of efficacy (80). Most investigators
have concluded that Pil are subject to such a high degree of
antigenic variation that a Pil-based vaccine is unlikely to
succeed. It is conceivable that relatively conserved domains
from a modest number of Pil variants might be useful in a
vaccine, and limited research continues with the aim of
exploring this possibility.
Other Possible Gonococcal Vaccines. Opacity proteins
(Opa) are a family of up to 11 or 12 related outer membrane
proteins that, like pili, also serve as adherence ligands,
undergo high-frequency phase and antigenic variations, and
appear to be necessary to establish genital infection (81). One
or a few Opa proteins appear to promote invasion of eukary-
otic cells (82). The molecular mechanisms for Opa variation
are quite different from Pil variations. Opa expression is
regulated by translational frameshifting, which is the conse-
quence ofhigh-frequency spontaneous variations in the num-
ber ofa pentameric CTCTT oligonucleotide repeat present in
the opa region encoding the signal sequence (83). Each of the
approximately 11 opa genes (84) is constitutively transcribed,
but most are not translated; at any time, a single cell
expresses zero to four or rarely five Opas. Each Opa contains
two regions of highly variable protein sequence (HV1 and
HV2), and expression of different opa genes results in
antigenic variation (83-85). Although mAbs against particu-
lar Opas decrease adherence (86, 87), no cross-reacting Opa
antibodies have been described that either block adherence
or have other potentially protective effects. Relatively little
work has been done on possible Opa vaccines, influenced no
doubt by considerations of difficulties encountered with the
highly antigenically variable Pil vaccine. If subsequent work
were to demonstrate that only one or at most a few Opas were
required to initiate or maintain infection (which has yet to be
proven), or if a common essential Opa domain were discov-
ered, this situation could change.
LOS is another potentially useful immunogen. Gonococcal
LOS has relatively typical core sugars, but no 0 antigen. The
terminal core sugar is a close molecular mimic of certain host
glycolipids (88). Antibodies against terminal core sugars are
bactericidal, and many persons who have never been ex-
posed to gonococci have serum IgM anti-LOS bactericidal
antibodies against many gonococci (89). Since gonococci do
not have a carbohydrate capsule (unlike closely related
meningococci), LOS core sugars are the only carbohydrate
antigens that might be considered for a vaccine. Unfortu-
nately, evolution has enabled gonococci to escape attack on
LOS, by at least three mechanisms. (i) Mimicry of host
antigens reduces immune response to certain epitopes (88).
(ii) Phase and antigenic variations affect the length and
composition of core sugars and loss of terminal epitopes
helps to evade antibodies against the core, although gono-
cocci with a truncated core are complement sensitive. These
variations occur at a frequency (-1 x 10-3) similar to Pil and
Opa variations (90). The genetics of LOS core variations are
not well understood. (iii) Sialylation of the terminal core
sugar occurs in vitro and in vivo (62, 91), when bacterial
sialyltransferase and host-derived CMP-N-acetylneuraminic
acid (CMP-NANA) as a substrate are used. Sialylation of the
terminal LOS core sugar results in partial masking of both
LOS and the physically proximate Por (56), inhibiting anti-
body attack on both LOS and Por. Sialylation also interferes
Cofloquium Paper: Sparling et al.
2460 Colloquium Paper: Sparling et al.
with effective formation of the terminal complement com-
plex, thereby inhibiting bactericidal activity of antibodies
against other nonmasked antigens such as Opa (56). Phase
variation ofcore sugar composition results in transient loss of
the terminal CMP-NANA acceptor site, and therefore, in-
ability to undergo sialylation. This in turn seems to result in
phase variation between a nonsialylated, invasive, but se-
rum-susceptible, phenotype and a sialylated noninvasive
serum-resistant phenotype (92).
On the basis of knowledge gained from studies of Por, Pil,
Opa, and LOS, an ideal vaccine candidate might be one that
does not undergo high-frequency antigenic variations, that is
not protected by anti-Rmp blocking antibodies, and that is
not masked by sialylation. It also should contain one or a few
epitopes that are conserved and that are targets for protective
antibodies. LOS seems a very unlikely candidate because of
mimicry, phase and antigenic variation, protection by block-
ing anti-Rmp antibodies, and masking by sialylation. Pili
seem to be too antigenically variable. Por remains a possible
candidate because of relatively stable expression of cross-
reactive epitopes for protective polyclonal and monoclonal
antibodies and rather weak epidemiologic evidence for partial
Por-based immunity, although partial protection by blocking
anti-Rmp antibodies and LOS sialylation are major problems.
Another candidate is one or both of the proteins that consti-
tute the transferrin receptor. Transferrin-binding protein 1
(Tbpl) is a 100-kDa protein (93), and transferrin-binding
protein 2 (Thp2) is an unrelated 85-kDa protein. Together,
these proteins constitute a specific and perhaps essential
receptor for binding transferrin and removing iron from it
(94). Expression of Tbpl and Tbp2 is repressed by iron, and
the structural genes tbpA and tbpB for Tbpl and Thp2,
respectively, appear to be part of an iron-regulated polycis-
tronic operon (J. Anderson, C. Cornelissen, and P.F.S.,
unpublished data). Comparison of the predicted protein se-
quences for Tbp1 in gonococci (93) and meningococci (95),
and for Tbp2 in gonococci (C. Cornelissen, J. Anderson, and
P.F.S., unpublished data) and meningococci (95) shows that
these proteins are closely related. Antibodies against men-
ingococcal Tbpl and Tbp2 block meningococcal transferrin
binding (96), cross-react rather broadly among meningococci
(97), and are bactericidal§. Similar studies have yet to be
conducted with gonococcal Thpl and Tbp2, but it is known
that sialylation of LOS does not mask the gonococcal trans-
ferrin receptor (unpublished data of C. Cornelissen and
P.F.S.). It is premature to do more than speculate about use
of transferrin receptor proteins in a gonococcal vaccine, but
the limited data are encouraging. IgAl protease might also be
considered on the basis of evidence that antibodies against
meningococcal IgA protease cross-react broadly and block
proteolytic activity (98).
CHLAMYDIA
C. trachomatis is an obligate intracellular bacterial pathogen
that causes trachoma and genital tract infections. There are
15 principal serovars arranged into three serogroups. Sero-
vars A, B, and C are responsible for most trachoma, and
serovars D through K cause most genital infections (urethri-
tis, cervicitis, salpingitis). Infection results in both protective
immunity and tissue-damaging hypersensitivity responses,
which has complicated efforts to develop vaccines. There has
been remarkable progress in understanding the immuno-
pathogenesis of chlamydia infections in the past decade, and
a vaccine for genital chlamydia is now a realistic hope.
Heat Shock Proteins and HypersenDivity. Important les-
sons were learned from attempts to develop a vaccine against
trachoma (reviewed in ref. 99 and 100). Ocular scarring and
blindness result from chronic and repeated infection. Sero-
var-specific immunity develops over time, but other serovars
remain infectious and trigger an apparent hypersensitivity
response. Attempts to prevent infection with a crude whole-
cell vaccine may actually have potentiated the hypersensi-
tivity response after reexposure to infection. Protection of
experimental animals from ocular infection was achieved
with mAbs against the major outer membrane protein
(MOMP), the serovar-specific typing antigen. An ocular
hypersensitivity response was elicited in guinea pigs with the
Chlamydia psittaci guinea-pig inclusion conjunctivitis agent
(101), and topical application of one protein, a 57-kDa heat
shock protein closely related to the groEL product (102),
triggered a delayed hypersensitivity response in previously
infected animals (103). Thus, the concept emerged that
certain antigens such as MOMP may be useful in a vaccine,
whereas others such as the 57-kDa GroEL homologue could
be harmful in a vaccine.
Genital chlamydia infections also tend to be chronic and
recurring and associated with scarring complications. Con-
siderable evidence links chlamydia (as well as gonococci) to
salpingitis, tubal infertility, and ectopic pregnancy. Tubal
infertility may occur even in the absence of acutely symp-
tomatic pelvic inflammatory disease, apparently due to smol-
dering and persistent chlamydia infection. Hypersensitivity
to the 57-kDa GroEL homologue may contribute to compli-
cations of infections, since there is a strong correlation
between presence ofantibodies to this heat-shock protein and
salpingitis (104), ectopic pregnancy (104), and tubal infertility
(105). Indeed, antibodies to this protein may be predictive of
women with chlamydia infection who will develop compli-
cations of infection (105). Women with salpingitis apparently
also are more likely to have a delayed hypersensitivity
response to the 57-kDa protein than other women with
chlamydia infection (106). In infected primates, the pathology
of diseased fallopian tubes is consistent with a cellular
hypersensitivity response (107).
Both B-cell and T-cell responses probably are important to
the protective immune response (99, 100, 108, 109). Inter-
feron y (IFN-y) plays a prominent role in protection against
genital chlamydia (110), and exciting recent evidence sug-
gests that IFN-y may result in a persistent, quiescent infec-
tion in which chlamydia express normal amounts of 57-kDa
GroEL homologue but markedly decreased amounts of
MOMP and other outer membrane antigens (111). If con-
firmed, this would help to explain how the immune response
leads to chronic infection, and subsequently to a tissue-
damaging hypersensitivity response to cross-reacting host
heat shock protein antigens. Similar mechanisms may be
involved in the arthritis-dermatitis-mucositis syndrome
(Reiter syndrome) that often complicates genital chlamydia
infection (112). It is unclear why the response is directed
particularly to fallopian tubes, joints, and certain other tis-
sues. Murine immune responses to chlamydial heat shock
proteins are H-2 linked (113) which could help to explain why
only a proportion of persons develop immune-related com-
plications, assuming similar genetic control ofanti-chlamydia
responses in humans.
MOMP as a Protective Antigen. There is at least partial
immunity to infection by the same strain after genital chla-
mydia infection in women (114), monkeys (115), and guinea
pigs (116). Recovery of chlamydiae from the cervix is in-
versely correlated with presence of IgA antibodies reactive
with C. trachomatis in cervical secretions (114), suggesting
IgA may be protective for genital chlamydia. Antibody to
several antigens is correlated with apparent protection
against postabortal chlamydia salpingitis (117), but the best
§Irwin, S., Jacobs, E., Danve, B., Quentin-Millet, M. J. & Schryvers,
A. B., Eighth International Pathogenic Neisseria Conference, Octo-
ber 4-9, 1992, Cuernavaca, Mexico, p. 50 (abstr.).
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evidence for antigen-specific protection concerns MOMP.
Anti-MOMP polyclonal and monoclonal antibodies are neu-
tralizing and protective against tissue culture infection by
elementary bodies, the infectious extracellular form of chla-
mydia, and against toxic death in mice (118-121). Some
MOMP mAbs neutralize more than a single serovar. Protec-
tion extends in some instances to subspecies specific epitopes
but not to all serogroups of chlamydia.
These results led to the cloning and sequencing of the
structural gene for MOMP from all serovars of C. tracho-
matis (122-124), with several important findings. MOMP is a
transmembrane protein, with four surface-exposed and vari-
able domains (VDI-VDIV) (125). Non-surface-exposed por-
tions of the expressed protein are highly conserved. Proteo-
lytic cleavage of VDII or VDIV reduces infectivity (126), as
do mAbs specific for variable domain epitopes (127-129). By
use of synthetic peptides, epitopes specific for neutralizing
MOMP mAbs have been mapped to short linear peptides on
the surface-exposed loops (100, 130). T-help (TH) epitopes
are located within conserved as well as variable domains of
MOMP (131, 132), as well as on other chlamydia proteins
(133).
A neutralizing epitope composed of seven amino acids
located in MOMP VDIV, when coupled to a common TH
epitope composed of MOMP amino acids 106-130, elicited
polyclonal antibodies in mice and cynomolgus monkeys that
bound to the surface of C. trachomatis serovars D, E, F, and
G, which cause about 80% of genital chlamydia infections,
and neutralized tissue culture infectivity (129). Six of eight
congenic mice that differed in major histocompatibility com-
plex class II haplotype developed anti-VDIV antibodies after
immunization, showing that there was not severe T-cell
restriction in immune response to this peptide (129). These
encouraging results suggest that a synthetic peptide vaccine
against genital chlamydia is possible. An analogous peptide
containing a TH epitope and aVDI neutralizing epitope shows
promise as a trachoma vaccine (134). The utility of purified
recombinant MOMP as a vaccine also is being explored (135,
136).
MOMP does not appear to be protected by blocking
antibodies or by strategies analogous to sialylation of LOS,
both of which at least partially protect Por in gonococci. This
suggests that it may prove to be easier to develop chlamydial
MOMP vaccines than gonococcal Por vaccines. Both MOMP
(124, 137) and Por appear to be subject to genetic drift,
although how serious a problem this may be for vaccines is
unclear.
Recently, a chlamydial 75-kDa outer membrane protein
has been identified as a member of the heat shock protein 70
family (138) and more specifically as a DnaK homologue
(139). Antibodies against this protein might be protective,
since polyclonal antisera react with surface-exposed epitopes
and are neutralizing in vitro (138). Moreover, there is a
correlation between presence ofantibodies to this antigen (as
well as several others) and apparent protection from salpin-
gitis (117). Unlike the 57-kDa GroEL homologue, the 75-kDa
protein does not trigger an ocular hypersensitivity response
in previously infected animals (140). Caution is warranted,
however, because it shares regions of similarity with a sperm
cell receptor (139).
PROSPECTS FOR THE FUTURE
It is much too early to predict future success for vaccines
against any bacterial STD. Prospects appear best for a
MOMP-based chlamydial vaccine, followed perhaps by a
gonococcal vaccine based on Por and/or other antigens. It
may be necessary to develop polyvalent vaccines, containing
multiple epitopes of a single molecule such as MOMP or Por.
This might be accomplished by synthetic peptide technology,
or by use of recombinant DNA methods to construct novel
chimeric proteins. It also may be necessary to combine
different antigens, although this would greatly increase the
number of possible vaccine candidate combinations to be
tested. Lack ofreally good animal models limits development
of vaccines for most of these infections, although there are
several good models in which to study chlamydia vaccines.
Delivery of a vaccine is another issue that will need to be
addressed, and it could be crucial to initial efforts to deter-
mine whether a vaccine candidate holds real promise and is
worth further development. Here, too, there is promise; a
MOMP VDI neutralizing peptide for trachoma serovar A has
been expressed in poliovirus, with evidence for strong im-
munogenicity in rabbits and production of high-titered neu-
tralizing antibodies (141). The ideal vaccine would decrease
transmission of the infection between partners and would
prevent complications of disease.
Bacterial STDs are common infections and they cause
important morbidity as well as potentiation ofHIV transmis-
sion. The effort to develop vaccines to prevent these infec-
tions is challenging and is a very important goal.
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